Cyclic guanosine
monophosphorothioate analogue 1a is
currently showing potential as a drug for the treatment of inherited
retinal neurodegenerations. To support ongoing preclinical and clinical
work, we have developed a diastereoselective synthesis via cyclization
and sulfurization of the nucleoside 5′-H-phosphonate
monoester, which affords the desired R
P-3′,5′-cyclic phosphorothioate in 9:1 ratio to the
undesired S
P-diastereomer. This route
was made viable as a result of the silyl protection sequence used,
which achieved >80% selectivity for 2′,5′-hydroxyls
over 3′,5′-hydroxyls. Finally, the chromatography-free
process allowed for a scale-up, as intermediates and the final product
were isolated by crystallization to give 125 g of 1a (13.8%
total yield) with over 99.9% HPLC purity.